Elamipretide TFA  (Synonyms: MTP-131 TFA; RX-31 TFA; SS-31 TFA)

Elamipretide TFA (MTP-131 TFA; RX-31 TFA; SS-31 TFA) is the TFA salt form of Elamipretide (HY-P0125). Elamipretide TFA is a mitochondria-targeting peptide, which ameliorates myocardial infarction, improves the renal function and protects neurons form inflammatory and oxidative stress injury^[1][2].

Cardiolipin peroxidase^[1]

Elamipretide TFA (5 mg/kg, i.p., once daily for 3 days) exhibits neuroprotective effects, protects the hippocampus from mitochondrial dysfunction, and attenuates the oxidative stress and inflammatory response in Lipopolysaccharide (HY-D1056)-induced cognitive impairment in C57BL/6 mice model^[1].

MedChemExpress (MCE) has not independently confirmed the accuracy of these methods. They are for reference only.

753.81

C₃₄H₅₀F₃N₉O₇

1606994-55-1

Solid

{d-Arg}-{Dmt}-Lys-Phe-NH2

{d-Arg}-{Dmt}-KF-NH2

Room temperature in continental US; may vary elsewhere.

Sealed storage, away from moisture

*In solvent : -80°C, 6 months; -20°C, 1 month (sealed storage, away from moisture)

• [1]. Zhao W, et al., Elamipretide (SS-31) improves mitochondrial dysfunction, synaptic and memory impairment induced by lipopolysaccharide in mice. J Neuroinflammation. 2019 Nov 20;16(1):230.  [Content Brief]

  [2]. Sabbah HN,et al., Chronic Therapy With Elamipretide (MTP-131), a Novel Mitochondria-Targeting Peptide, Improves Left Ventricular and Mitochondrial Function in Dogs With Advanced Heart Failure. Circ Heart Fail. 2016 Feb;9(2):e002206.  [Content Brief]